Late in gestation, the fetal lung undergoes marked changes in preparation for extrauterine life. These include enlargement of potential airspaces, septal thinning (1), differentiation of the pulmonary epithelium (2) , maturation of the surfactant system (3, 4) , endothelial proliferation, formation of new blood vessels, and alignment of pulmonary capillaries in close proximity to distal airspaces (5, 6) to facilitate postnatal gas exchange. These processes must be tightly regulated by factors that provide mitogenic signals as well as organizational information (7, 8) .
Formation of the pulmonary vasculature begins at the earliest stages of lung development, continues throughout gestation (6), requires complex interaction among different tissues, and is controlled by spatial and temporal expression of numerous growth factors and their receptors (9, 10) . Of particular interest is VEGF. The VEGF family consists of five members, VEGF-A, -B, -C, -D, and placental growth factor (reviewed in 11). VEGF-A, the first described and most extensively studied, is involved in angiogenesis, cell proliferation, cell migration, and vascular permeability (11) . Deletion of VEGF-A or either of its receptors, Flt-1 and Flk-1 (11) , results in embryonic lethality from disruption of vascular development (12) (13) (14) (15) . In early embryonic life, VEGF-A is expressed widely, but in later gestation is expressed mainly in lung, heart, kidney, vertebral column, and brain (16) ; postnatally, lung has the highest expression (17) . VEGF-A mRNA is alternately spliced into at least four isoforms, VEGF-A 188 , -164 , -144 , and -120 in mouse and rat (18, 19) . Isoform expression varies by tissue and stage of development (20 -23) . In fetal lung, VEGF-A 188 expression is low until late gestation, when it increases rapidly to become the dominant isoform just before birth and postnatally. In contrast, VEGF-A 120 and -164 are abundantly expressed in mid-gestation; then their expression progressively decreases (21, 23) .
In prenatal lung, VEGF-A mRNA is expressed in mesenchymal and epithelial cells in mid-gestation, but primarily in epithelial cells in late gestation and postnatally (23-26). VEGF-A affects endothelial cell proliferation and differentiation through its receptors, Flt-1 and Flk-1, located on endothelial cells and their precursors (6, 14, 26) . Recent studies indicate that VEGF-A and its receptors are essential not only for vascular development but also for normal pulmonary parenchymal development, both morphologic (27,28) and functional (29). Both Flt-1 and Flk-1 have been detected recently in distal lung epithelial cells, a finding that supports the role of VEGF as an autocrine as well as paracrine regulator of lung development (30,31).
Fetal lung development is profoundly influenced by mechanical factors, in particular, lung distension. Increased distension (which stretches lung cells), produced by fetal tracheal occlusion, accelerates lung growth and morphologic maturation but retards differentiation of alveolar type 2 cells and surfactant formation (32-35). In contrast, decreased distension retards lung growth and morphologic maturation and favors expression of the type 2 cell phenotype compared with type 1 cells (32,36). A relatively common cause of decreased fetal lung distension, congenital diaphragmatic hernia (CDH), causes pulmonary hypoplasia and abnormal pulmonary vascular development (fewer vessels and increased arteriolar medial musculature) that lead to persistent pulmonary hypertension after birth (37) . In experimental animals with CDH, similar vascular abnormalities occur (38 -40), and fetal tracheal occlusion reverses some of these abnormalities (41-43).
Mechanical factors also influence VEGF expression in lung tissue. Cyclic mechanical stretch increases expression of VEGF mRNA and protein in cultures of ovine pulmonary vascular smooth muscle cells (44) and in mixed pulmonary cell cultures from fetal and postnatal mouse lungs (45) . Previous in vivo studies of CDH induced by maternal administration of nitrofen have given conflicting results, with CDH either decreasing VEGF protein (46, 47) or increasing VEGF mRNA and protein (48) . A concern with some of those studies is that control animals were not exposed to nitrofen, an agent known to alter vascular and parenchymal development in fetal lung (49, 50) .
As noted above, tracheal occlusion reverses some of the pulmonary vascular abnormalities in CDH (41-43) and, in vitro, cyclic stretch increases expression of VEGF-A mRNA in pulmonary vascular smooth muscle cells (44) and mixed pulmonary cell cultures (45) . Based on those studies, we hypothesized that decreased distension of the fetal lung by CDH would reduce VEGF-A expression and that increased lung distension by tracheal occlusion would have the opposite effects. As background for the proposed studies, we also defined the expression of VEGF-A, its isoforms and its receptors in developing lung, as these data have not previously been described for the rat.
MATERIALS AND METHODS
Animals. All studies were approved by the Committee on Animal Research of the University of California, San Francisco, and all procedures conformed with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Timed pregnant Sprague-Dawley rats (Charles River Laboratories, Hollister, CA) were housed in a laminar flow facility (ambient temperature 21°C) and were provided feed and water ad libitum. We studied 108 fetal rats from 34 pregnant dams, as well as 5 postnatal rats.
Developmental studies. Pregnant dams and their fetuses were anesthetized with maternal intramuscular injections of ketamine (Parke-Davis, Morris Plains, NJ; 180 mg/kg) and xylazine (Butler, Columbus, OH; 2.5 mg/kg). Thirty minutes after administration of anesthetic, fetuses were delivered by hysterotomy on ED 16, 19, and 22 (term). Each fetus was pithed and weighed; the lungs were dissected free from heart and trachea, weighed, snap frozen in liquid nitrogen and stored at -80°C for future studies. After delivery of all fetuses, dams were euthanized by intracardiac injection of pentobarbital (Euthanasia Solution, Schering-Plough Animal Health Corp., Union, NJ; 1 mL, 390 mg/mL solution) followed by production of bilateral pneumothoraces. Postnatal animals were anesthetized as described above. Their lungs were removed at PD 5, 10, and 21, and from adult animals.
Tracheal occlusion. On d 20 of gestation (presence of a vaginal plug indicated d 1), dams and fetuses were anesthetized. Through a maternal midline laparotomy, TO was performed on fetuses as previously described (51) . Briefly, a section of uterine horn was exposed, a purse string suture (6 -0 polypropylene) was placed in the uterus near the fetal head, and the fetal head and neck were exteriorized through a small hysterotomy. Using an operating stereomicroscope, the trachea was exposed and cauterized using a hand-held cautery unit equipped with a microtip. The fetus was returned to the amniotic sac, the purse string suture tightened and the maternal abdomen closed in two layers. With each dam, we performed TO in four fetuses (TO group) and sham operations in two (trachea exposed but not cauterized, Sham group); unoperated littermates were controls (Control group). At ED 22 (term), fetuses were delivered and weighed; their lungs were removed, weighed and frozen as described above. In some fetuses (TO and Control), lungs were prepared for immunohistochemical analysis as described below. In fetuses with TO, lungs were examined for signs of distension (i.e. successful TO); these included large lungs with indentations on the pleural surface from the rib cage, and/or fluid accumulation. Fetuses without distended lungs were excluded from the TO group. After delivery of all fetuses, dams were euthanized as described above.
Congenital diaphragmatic hernia. To produce fetal CDH, timed-pregnant rats (gestation 9.5 d) were gavage fed nitrofen (2,4-dichloro-4'-nitrodiphenyl ether, Wako Chemicals, Osaka, Japan), 100 mg dissolved in 1 mL of olive oil. This produces CDH in 40 -60% of fetuses (52) . In some dams, TO was performed on fetuses at ED 20 as described above. On ED 22, fetuses were delivered, weighed, the abdominal cavity was opened and presence or absence of CDH was determined by visual inspection of the diaphragm. Lungs were removed, and left and right lungs were separated, weighed, snap frozen, and stored at -80°C for future study. Lungs from these fetuses were separated into three groups: CDH (fetuses with left-sided CDH), nitrofen controls (NC, fetuses exposed to nitrofen that did not have CDH), and CDH ϩ TO (fetuses with left-sided CDH and TO).
RNA isolation and RT-PCR. Total RNA was isolated from whole lung by the RNAzol method (Tel-Test, Inc., Friendswood, TX) as previously described (36). Multiplex RT-PCR was used for analysis of Flt-1 and Flk-1 mRNA in combination with 18S rRNA levels in fetal lung utilizing Competimer technology (Ambion, Austin, TX). Total RNA (0.125 g) was reverse transcribed using random primers. cDNA was amplified with specific oligonucleotide primers for Flt-1 and Flk-1 as previously described (53) and 18S rRNA (QuantumRNA 18S Internal Standards, Ambion). For each gene, we determined the linear range (Flt-1 20 cycles, Flk-1 28 cycles) and the optimal 18S Primer:Competimer ratio (1:9 for Flt-1 and Flk-1). Radiolabeled PCR products were produced using direct incorporation of ␣-32 P-dCTP (3000 Ci/mmol, NEN, Boston, MA) during amplification. PCR products were resolved on 6% polyacrylamide gels containing 8 M urea. After drying the gel, we quantified PCR products using the Storm 840 phosphorimager and ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
Differential splicing of the VEGF-A gene allows for amplification of four isoforms in a single reaction using oligonucleotide primers directed against 31 VEGF-A AND FETAL LUNG DISTENSION exons 1 and 8 (18) . These primers produce PCR products of 564, 492, 432, and 342 base pairs in length corresponding to VEGF-A proteins of 188, 164, 144, and 120 amino acids, respectively (18, 19) . VEGF-A mRNA isoform expression was quantified by RT-PCR as described above except that 18S rRNA levels were determined on the same cDNA sample in a separate tube due to difficulties in multiplexing with these primers. Linear ranges were determined for each and were 20 cycles for all VEGF-A isoforms and 7 cycles for 18S rRNA.
VEGF-A protein.
Whole lungs were homogenized with the aid of a Dounce homogenizer in 1 mL of 20 mM Tris, pH 8.0, 137 mM NaCl, 1% Triton X-100, 10% glycerol containing protease inhibitors (Broad Specificity Protease Inhibitors, Catalogue #P8340, Sigma Chemical Co., St. Louis, MO). Insoluble material was pelleted by microcentrifugation at 16,000 g for 30 s and supernatant was assayed for protein concentration using the bicinchoninic acid modification of the Lowry method (Sigma Chemical Co.) (36). VEGF-A protein levels were determined using the Quantikine M, mouse VEGF Immunoassay kit (R & D Systems, Minneapolis, MN) according to manufacturer's instructions. This assay recognizes both the 164 and 120 amino acid forms of rat VEGF-A. Serial dilutions (50, 25, and 12.5 L of supernatant) were assayed in triplicate and values were expressed as picograms VEGF per milligram total lung protein.
Immunohistochemistry. Fetal rat lungs from TO fetuses and littermate Controls were fixed in 4% paraformaldehyde in situ at a constant intratracheal pressure of 10 cm H 2 O for 4 h and processed as previously described (36). Immunohistochemistry was performed on 3-m sections of fixed, cryoprotected rat lung using a primary antibody to VEGF-A. Sections were treated with 1% H 2 O 2 for 10 min at room temperature and washed with 20 mM Tris-buffered 0.9% NaCl, pH 7.4 (TBS). Antigen retrieval was performed in 10 mM Na Citrate, pH 6.0 (Target Retrieval Solution, DAKO, Carpinteria, CA) at 95°C for 10 min followed by a cooling phase of 20 min at room temperature. Sections were washed with TBS and incubated with blocking solution (TBS/ 0.1% BSA/0.3% Triton X-100/10% rabbit serum) for 1 h at room temperature to block nonspecific binding. Sections were incubated with C-1 anti-VEGF MAb (Santa Cruz Biotechnology, Santa Cruz, CA), diluted 1:500 in TBS/0.1% BSA/0.3%Triton/1.5% rabbit serum, at 4°C overnight. After extensive washing in TBS/0.1% BSA/0.3% Triton X-100, sections were incubated with biotin-conjugated rabbit anti-mouse IgG for 1 h at room temperature. To control for nonspecific staining, we also processed sections with omission of either the primary antibody or primary and secondary antibodies. To visualize the histochemical localization of VEGF-A, we used the Vectastain ABC Kit (Vector Laboratories, Burlingame, CA) and the DAB (3,3'-diaminobenzidine) Substrate Kit. To label nuclei, sections were counterstained with Gill's No. 2 hematoxylin (Sigma Chemical Co.). Sections were air dried, mounted with Glycergel (DAKO) and analyzed with a Leitz Orthoplan 2 microscope. To identify which pulmonary epithelial cells contained VEGF-A protein, we used serial lung sections either to label VEGF-A or, using double indirect immunofluorescence, to label RTI 40 and RTII 70 , proteins specific in the lung to the apical membranes of rat type I and type II pneumonocytes, respectively; sections were processed as previously described (36).
Statistical analyses. Data for the gestational series were analyzed over time by linear regression. Values for experimental groups (TO, SHAM and Control, or CDH, CDHϩTO, and NC) were compared by ANOVA using Fisher's Protected Least Significant Difference or Bonferroni/Dunn post hoc test where appropriate. Data are presented as percent Ϯ SD of the relevant control values. All statistical analyses were done using StatView (Abacus Concepts Inc., Berkeley, CA). Statistical significance was assumed for p values Ͻ0.05.
RESULTS
Developmental studies. We examined expression of VEGF-A isoforms and their receptors, Flt-1 and Flk-1, in lungs from fetal (ED 16, 19, and 22) and postnatal (PD 5, 10, 21, and adult) rats (n ϭ 1 for each time point). Levels for each VEGF-A isoform were calculated both as percentage of 18S rRNA and as percentage of total VEGF-A message. Relative to 18S, all VEGF-A isoforms were expressed at low levels at ED 16 ( Fig. 1A) and increased with development with highest expression after PD 5 (Fig. 1B) ; thus, total VEGF-A mRNA increased throughout development. For individual isoforms, the increase was significant only for VEGF-A 188 (r 2 ϭ 0.721, p ϭ 0.032). In Figure 1A , the bands for VEGF-A 188 and -144 at ED 16 and 19 are difficult to see; however, clear signals were detected with quantitation by phosphorimager (Fig. 1B) . When calculated as percentage of total VEGF-A mRNA, the isoforms showed different expression patterns (Fig. 1C) . VEGF-A 188 was low at ED 16 and then progressively increased through PD 21 (r 2 ϭ 0.902, p ϭ 0.004) to become equivalent to VEGF-A 164 at PD 10 and 21 and dominant in adulthood. VEGF-A 164 , the dominant form at ED 16, tended to progressively decrease (r 2 ϭ 0.565, p ϭ 0.084) at PD 21 and in adulthood. There were significant decreases from ED 16 to PD 21 for both VEGF-A 144 (r 2 ϭ 0.661, p ϭ 0.049) and -120 (r 2 ϭ 0.900, p ϭ 0.004). Expression patterns of Flt-1 and Flk-1 relative to 18S in the same lungs are shown in Figure 2 . Flt-1 mRNA expression increased more than 5-fold throughout development (r 2 ϭ 0.792, p ϭ 0.017) and was maximal in adult lung. Although expressed at lower levels, Flk-1 also increased throughout development (r 2 ϭ 0.890, p ϭ 0.004) but showed only a 2-fold increase. For all of the above regressions, we excluded the adult values because we were uncertain of the actual age of the adult animal. However, all values are shown in Figures 1 and  2 . Analysis of serial lung sections labeled for detection of either VEGF-A or RTI 40 and RTII 70 showed that VEGF-A protein was present in interstitial cells as well as in both type I and type II pneumonocytes (Fig. 3) . No staining was seen with omission of the primary antibodies against VEGF-A, RTI 40 and RTII 70 (data not shown).
Tracheal occlusion. We studied 36 fetuses from 14 dams. Data were analyzed from three experimental groups: TO (n ϭ 10), Sham (sham-operated littermates, n ϭ 11), and Control (unoperated littermates, n ϭ 15). Fetal body weights were similar among the three experimental groups (Table 1) . Compared with Sham and Control fetuses, TO significantly increased wet lung weight, both in absolute terms (grams) and as a percentage of body weight (Table 1) . These effects were similar among male and female fetuses (data not shown). When calculated as percentages of 18S rRNA, all four isoforms of VEGF-A mRNA were significantly increased in lungs of TO fetuses compared with Control fetuses (Fig. 4, A and B (Fig. 4C ). In the same lungs, we examined expression of the VEGF-A receptors, Flt-1 and Flk-1. Although TO caused no significant changes in mRNA expression of either receptor, on microscopic examination of the lungs, TO increased the size of the distal potential airspaces (Fig. 5) . By immunohistochemistry, VEGF-A appeared increased both in epithelial cells and in interstitial tissue of distal parenchyma in TO fetuses (Fig. 5) .
Congenital diaphragmatic hernia. We studied 36 fetuses from 10 dams. Fetuses were divided into three groups: NC (Nitrofen Control, exposed to nitrofen with no CDH, n ϭ 18), CDH (left-sided CDH, n ϭ 15), and CDH ϩ TO (left-sided CDH with TO, n ϭ 3). Because of the small number of CDH ϩ TO fetuses, the results for that group should be interpreted with caution, and we have not included statistical analyses of the results from that group. Fetal body weights were similar among the three experimental groups (Table 3) . CDH significantly decreased lung weight. These effects were similar among male and female fetuses (data not shown). Lung weights from CDH ϩ TO fetuses were greater than NC and CDH fetuses (when calculated as percentage body weight, Table 3 ). For the following studies, only the lung ipsilateral to the CDH (i.e. left lung) was used for analysis. When expressed as a percentage of 18S rRNA, none of the mRNA for the four VEGF-A isoforms showed significant differences among the three experimental groups (Fig. 6, A and B) . However, when expressed as a percentage of total VEGF-A mRNA, all isoforms showed significant changes (Table 4 ). CDH decreased VEGF-A 188 , increased VEGF-A 164 and -120 , and did not affect VEGF-A 144 compared with both NC and CDHϩTO. Furthermore, CDH ϩ TO apparently restored expression of VEGF-A 188 and -164 to levels similar to NC, increased VEGF-A 144 above NC and decreased -120 to levels below NC. CDH significantly decreased lung content of VEGF-A protein (Fig.  6C) ; VEGF-A protein was not assayed in CDH ϩ TO fetuses due to the small number of available fetuses. CDH did not affect expression of mRNA for the VEGF-A receptors, Flt-1 and Flk-1 (data not shown). 
VEGF-A AND FETAL LUNG DISTENSION

DISCUSSION
VEGF-A and its receptors are necessary for embryonic survival (12) (13) (14) (15) and play essential roles in pulmonary vascular and parenchymal development (27-29,54). In addition, changes in fetal lung distension have marked effects on lung parenchyma (32-36,51) and vasculature (37,39 -43,49) . We designed the present studies to examine the expression of VEGF-A, its isoforms, and its receptors in developing rat lung and to investigate effects on these critical factors by changes in distension of the fetal lung.
Our results for the developmental pattern of lung expression of the VEGF-A isoforms are similar to those reported previously in baboons (55), mice (23), and rabbits (56) . The timing of the postnatal increase in expression in the rat coincides with the period of alveolarization.
The similarity in expression patterns of the VEGF-A isoforms in developing lung across different species is consistent with previous studies showing that normal lung development is dependent upon tight control of the expression of the VEGF-A isoforms both temporally and spatially (28,54,57). The VEGF-A isoforms differ in solubility, heparin binding, receptor affinity, and biologic function (11, 58, 59) . The roles of the various VEGF-A isoforms in lung development have been incompletely defined, but some information is available from studies in transgenic mice. VEGF-A 164 and -188 are essential for normal vascular and parenchymal development. In the absence of these two isoforms, there is a reduction in the number of airspaces and capillaries (23) and retardation of parenchymal development so that the newborn mice die of respiratory distress due to surfactant deficiency (29). In contrast, with increased expression of VEGF-A 164 , there is increased vascular development (28,57), a decrease in branching morphogenesis, and decreased type I cell differentiation (28); these effects show variation between distal and central lung areas (54) .
In a pattern similar to VEGF-A mRNA, expression of mRNA for the VEGF-A receptors, Flt-1 and Flk-1, increased significantly with advancing gestation and these increases continued after birth (Fig. 2) . The progressively increasing expression of the VEGF-A receptors occurs during the period that lung vasculature is undergoing rapid development, findings consistent with previous reports in baboons (55) , mice (60) , and rats (9, 61) .
TO was performed to examine effects on VEGF-A of increased distension of the fetal lung. As previously reported (51, 62) , TO increased fetal lung weight but did not affect fetal body weight (Table 1) . TO increased expression of total VEGF-A mRNA and of its four isoforms when normalized to 18S rRNA, (Fig. 4, A and B) . In addition, TO accelerated the normal maturation changes in the relative expression patterns of VEGF-A isoforms (i.e., increase in VEGF-A 188 and decrease in VEGF-A 164 ; Table 2 ). TO also increased the lung concentration of VEGF-A protein (Fig. 4C) . Therefore, in addition to being a potent stimulus to lung growth (32,34, 51, 52, 63) and to hastening morphologic maturation of lung parenchyma (32-34,51,52), TO accelerates the maturational patterns of expression of total VEGF-A mRNA and its isoforms that occur in normal fetuses.
Our studies do not provide information as to which cells are responsible for the increased lung expression of VEGF-A with TO. However, based on data from the present studies and previous reports, it seems likely that both vascular and parenchymal tissues are involved. Quinn et al. (44) demonstrated that cyclic stretch increases VEGF-A mRNA in cultures of ovine pulmonary vascular smooth muscle cells, and Muratore and associates (45) reported similar results with cyclic stretch of cultures of mixed pulmonary cells from fetal, neonatal, and adult mice. However, TO causes tonic lung distension, and there is no information available about the in vitro effects on VEGF-A expression of tonic stretch of lung cells. Additional studies will be needed to determine whether tonic stretch has effects on VEGF-A expression that are similar to those of cyclic stretch in vitro. Gonzalez et al. (64) recently demonstrated that both alveolar type I and type II cells isolated from rat lung express VEGF-A mRNA. Our immunohistochemical studies show that TO increased VEGF-A protein in distal pulmonary epithelial cells, as well as in interstitial cells (Fig.  5 ). Specific staining of type I and type II pneumonocytes shows that VEGF-A protein is present in both types of distal pulmonary epithelial cells (Fig. 3) . It is of note that Gonzalez and associates (64) reported that the dominant isoform of VEGF-A mRNA is VEGF-A 188 in type I cells and VEGF-A 120 in type II cells. TO decreases type II cell density (32,33,35) and function (34,35) and stimulates differentiation of pulmonary epithelium into type I cells in fetal rats (51) . Therefore, the finding of increased expression of VEGF-A 188 with TO in the present study is consistent with type I cells participating in the effects of TO on VEGF-A expression. In contrast to the stimulatory effects on VEGF-A, TO did not significantly influence expression of Flt-1 or Flk-1.
With CDH, the diaphragmatic defect permits herniation of abdominal organs into the thorax, compressing the lungs and decreasing distension of the fetal lung. In our study, this resulted in pulmonary hypoplasia (Table 3) but did not affect fetal body weights, findings consistent with the previous report by Kitano et al. (52) . In contrast to effects of increased lung distension from TO as discussed above, CDH did not affect expression of total VEGF-A mRNA nor its isoforms when normalized to 18S rRNA (Fig. 6, A and B) . However, CDH did significantly affect relative expression patterns of VEGF-A isoforms (expressed as percentage of total VEGF-A mRNA); VEGF-A 188 decreased and VEGF-A 164 and -120 increased (Table 4). These changes due to CDH are the opposite of both the normal developmental pattern during the last few days of gestation (Fig. 1C) and changes induced by TO (Table 3) . Previous reports of the effects of CDH on VEGF-A expression have yielded conflicting results, and, because of differences in experimental methods, direct comparisons with our results are difficult. Chang et al. (65) reported that with CDH there was a decrease in the number of fetal lung cells expressing VEGF-A. However, they pooled lungs from nitrofen-exposed fetuses with and without CDH and compared them to control fetuses not exposed to nitrofen. Nitrofen is known to have potent effects on pulmonary parenchymal and vascular development independent of the presence of CDH (49, 50) , including a decrease in VEGF-A expression (66) . In contrast, Oue et al. (48) reported that lungs of fetal rats with CDH had increased expression of VEGF-A 120 , -164 , and -188 mRNA. These results are similar to ours with regard to relative expressions of VEGF-A 120 and -164 ; however, our study showed a decrease in relative expression of VEGF-A 188 and no change in expression of total VEGF-A mRNA. The reasons for these differences are not apparent but may be related to differences in experimental Data are mean Ϯ SD. Experimental group: CDH, fetus with congenital diaphragmatic hernia; CDH ϩ TO, fetus with CDH and tracheal occlusion; NC, nitrofen control (fetus exposed to nitrofen but without CDH). n, number of fetuses; %BW, lung weight as a percentage of fetal body weight. There were no significant differences in fetal body weights among the three experimental groups. § p Ͻ 0.02 vs NC; † p Ͻ 0.005 vs NC. Furthermore, consistent with previous reports (46, 47) , CDH decreased the amount of VEGF-A protein in the lung (Fig. 6C) , an effect opposite that of TO (Fig. 4C) . Our results for VEGF-A protein do conflict with those of Shehata et al. (67) , who reported increased VEGF in lungs of human infants with CDH who died after a period of assisted ventilation with high concentrations of oxygen; in that study, VEGF protein was assessed semiquantitatively by immunohistochemistry. The reasons for the differences between their results and our findings are not apparent, but may relate to species differences, changes in VEGF that occurred with birth and as a result of assisted ventilation in the human infants, and the method of assessing VEGF content in the lung (i.e. semiquantitative immunohistochemistry versus quantitative immunoassay).
To determine whether TO could reverse the effects of CDH on VEGF-A expression, we performed TO in fetuses with CDH. In fetuses with CDH, addition of TO significantly increased lung weights to greater than those from CDH fetuses as well as from nitrofen-exposed fetuses without CDH (Table  3) . Additionally, in CDH ϩ TO fetuses, there was apparent reversal of the effects of CDH on VEGF-A isoforms so that their relative expression patterns were similar to those in control fetuses (Table 4) .
In contrast to effects on VEGF-A mRNA and protein, CDH did not affect expression of Flt-1 or Flk-1. Our results show that in developing fetal and postnatal rat lung, as in other species (23, 55, 56) , there are clear maturational patterns in the expression of VEGF-A and its isoforms. These maturational patterns are disrupted by changes in distension of the fetal lung. Increased lung distension (by TO) accelerates and decreased lung distension (by CDH) retards the normal maturational expression patterns. Furthermore, increased lung distension enhances lung content of VEGF-A protein, and decreased distension has the opposite effect. Thus, mechanical factors, shown previously to affect growth (32,34,36,62), morphologic maturation (34,35), and epithelial differentiation (33,35,36,51) of fetal lung, also markedly influence pulmonary expression of VEGF-A, an angiogenic factor that is critical for normal pulmonary vascular and parenchymal development. Previous studies have shown that TO can reverse some of the pulmonary vascular abnormalities that occur with CDH (41-43), including decreasing arterial muscularization (41,42) and vascular impedance (43). The present studies suggest that these effects are mediated by changes in VEGF-A expression. Furthermore, because VEGF-A has important nonvascular pulmonary effects (27,29), it is likely that some of the parenchymal effects caused by changes in lung distension are also mediated by VEGF-A. Although our studies do not provide information on the mechanism(s) by which changes in lung distension affect VEGF-A expression, it is reasonable to suggest that other growth factors are involved. Several growth factors up-regulate VEGF-A mRNA expression, including IGF (11); in this regard, increased lung distension in fetal sheep increases lung expression of IGF-I (34) and IGF-II (63) .
In summary, changes in distension of the fetal lung have marked effects on expression of VEGF-A and its isoforms, factors that play essential roles in the normal development of pulmonary vasculature and parenchyma. Increased distension accelerates the normal maturational pattern of expression of VEGF-A, whereas decreased lung distension has the opposite effects. Tracheal occlusion reverses the high impedance to flow in the fetal pulmonary circulation and normalizes its physiological response to oxygen at full term. J Pediatr Surg 33:1071-1075
